STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

UTHR insider notice: 90,000 shares ($40.78M) to be sold on 10/06/2025

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

United Therapeutics (UTHR) filed a Form 144 reporting a proposed sale of 90,000 common shares, to be executed through Morgan Stanley Smith Barney LLC on 10/06/2025 on NASDAQ. The shares were acquired and paid for on 10/06/2025 through an exercise of stock options and funded in cash. The filing lists the aggregate market value of the shares as $40,776,300.00 and total shares outstanding as 45,226,262.

The notice also discloses multiple Rule 10b5-1 sales attributed to Michael Benkowitz during September 2025 totaling several transactions (examples: 7,875 and 14,625 share blocks) with gross proceeds reported per trade. The filer affirms no undisclosed material nonpublic information and includes the standard signature/attestation language required by the form.

Positive

  • Transaction transparency: Form 144 discloses the full sale amount of 90,000 shares and $40,776,300.00 aggregate market value
  • Use of 10b5-1 plans for prior September 09/2025 sales indicates pre-arranged disposition consistent with compliance practices

Negative

  • Large block relative to float: 90,000 shares represent a notable package against 45,226,262 outstanding shares
  • Concentration of sales by an insider in a short period (09/2025 trades plus this 10/06/2025 sale) could increase short-term supply pressure

Insights

TL;DR: An insider plans a large post-exercise sale of newly exercised options alongside recent 10b5-1 trades.

The filing reports the proposed sale of 90,000 shares acquired by exercise of stock options on 10/06/2025

These shares carry an aggregate market value of $40,776,300.00, representing a meaningful block versus the reported 45,226,262 outstanding shares. Recent 10b5-1 sales by Michael Benkowitz in 09/2025 show systematic disposition activity in smaller tranches with material gross proceeds per trade.

Key dependencies include the execution price and timing on 10/06/2025 and whether additional scheduled 10b5-1 trades remain active; monitor transaction settlement and exchange reporting within days following the stated sale date.

TL;DR: The Form 144 is procedural and includes the standard attestation against undisclosed material information.

The notice uses the required attestation language that the selling person does not possess undisclosed material adverse information as of the signatory date. The sale is routed through Morgan Stanley Smith Barney LLC and is designated for NASDAQ execution on 10/06/2025.

From a governance perspective, the presence of documented 10b5-1 sales in 09/2025 supports a pre-arranged trading plan for at least one insider. Confirmatory filings and broker confirmations after 10/06/2025 will complete the public record for compliance review.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does the UTHR Form 144 report on 10/06/2025?

The filing reports a proposed sale of 90,000 common shares acquired by exercise of stock options and paid in cash, to be sold on 10/06/2025 on NASDAQ.

How much is the aggregate market value of the shares in the UTHR Form 144?

The aggregate market value reported is $40,776,300.00 for the 90,000 shares.

Who is the broker handling the proposed UTHR sale?

The broker listed is Morgan Stanley Smith Barney LLC, Executive Financial Services, New York, NY.

Were there recent insider sales for UTHR before this filing?

Yes. Multiple Rule 10b5-1 sales by Michael Benkowitz occurred in 09/2025, including blocks of 7,875, 14,625, 6,125, and others with gross proceeds reported per trade.

How many shares outstanding does the filing state for UTHR?

The filing lists 45,226,262 shares outstanding.
United Therapeutics Corp.

NASDAQ:UTHR

UTHR Rankings

UTHR Latest News

UTHR Latest SEC Filings

UTHR Stock Data

21.03B
42.14M
1.77%
99.51%
5.97%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States
SILVER SPRING